Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions.

Molica, Stefano; Sportoletti, Paolo; Di Renzo, Nicola; Musto, Pellegrino; Pane, Fabrizio; Di Raimondo, Francesco

Molica, Stefano; Sportoletti, Paolo; Di Renzo, Nicola; Musto, Pellegrino; Pane, Fabrizio; Di Raimondo, Francesco.

Molica S; Department Hematological-Oncology, Azienda Ospedaliera Pugliese-Ciaccio, Catanzaro, Italy.
Sportoletti P; Centro di Ricerca Emato-Oncologica (CREO), University of Perugia, Perugia, Italy.
Di Renzo N; U.O.C. Ematologia, Presidio Ospedaliero Vito Fazi, Lecce, Italy.
Musto P; Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Aldo Moro" University School of Medicine, 70124 Bari, Italy.
Pane F; Department of Clinical Medicine and Surgery, Hematology Unit, Federico II University Medical School, Naples, Italy.
Di Raimondo F; Division of Hematology, Department of Surgery and Medical Specialties, University of Catania, Policlinico, Italy.

Mediterr J Hematol Infect Dis ; 13(1): e2021042, 2021.

Article in English | MEDLINE | ID: covidwho-1314825

Keywords

CLL; Venetoclax-rituximab; symptomatic COVID19; time-limited therapy

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Journal: Mediterr J Hematol Infect Dis Year: 2021 Document Type: Article Affiliation country: Mjhid.2021.042

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google